Skip to content

Clinical trials

Psoriasis trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Psoriasis Country / region: China Clear all

128 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20092
20121
20133
20143
20153
20162
20176
20184
201910
20208
202113
202210
202319
202415
202519
202610

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed67
Unknown status22
Recruiting19
Not yet recruiting8
Active, not recruiting6
Terminated4
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Xijing Hospital8
Guangdong Provincial Hospital of Traditional Chinese Medicine6
Bristol-Myers Squibb5
Second Affiliated Hospital, Zhejiang University, School of Medicine5
Akeso4
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.4
Ganzhou Hemay Pharmaceutical Co., Ltd4
Hansoh BioMedical R&D Company4
Innovent Biologics (Suzhou) Co. Ltd.4
Newsoara Biopharma Co., Ltd.4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Psoriasis128
Skin Diseases5
Drug-Related Side Effects and Adverse Reactions4
Pruritus4
Acne Vulgaris2
Bone Diseases, Metabolic2
Eczema2
Lymphoma, Follicular2
Aggressive Periodontitis1
Arthritis1

Trials

Showing 26 to 50 of 128. Each trial links to its page on Pharma Observatory.

28 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.